Eyevensys Announces Positive Preclinical Data Demonstrating Superiority of EYS809 over Aflibercept for Wet Age-Related Macular Degeneration (AMD) at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Eyevensys Announces Positive Preclinical Data Demonstrating Superiority of EYS809 over Aflibercept for Wet Age-Related Macular Degeneration (AMD) at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting https://eyevensys.com/wp-content/uploads/2020/02/verne-ho-0LAJfSNa-xQ-unsplash-1.jpg 2500 1667 Eyevensys https://eyevensys.com/wp-content/uploads/2020/02/verne-ho-0LAJfSNa-xQ-unsplash-1.jpgParis, France, and Cambridge, Mass., United States, April 24, 2023 – Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases,…